MetaVia Inc. (MTVA) is a Healthcare · Biotechnology company listed on NASDAQ. Price $1.67 (+5.03%), Market cap $0.01B, 52-week low–high $0.60 ~ $11.52.
MetaVia Inc., a clinical-stage biotechnology company, focuses on developing novel pharmaceuticals to treat cardiometabolic diseases. The company develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, as well as completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus; and DA-1726, a novel oxyntomodulin analogue functioning as a GLP-1 receptor and glucagon receptor dual agonist, which is in Phase 1 trial for the treatment of obesity. Its therapeutic programs include ANA001, a proprietar
Financial statements, price targets, institutional (13F) holdings and related news for MetaVia Inc. are updated in real time on BlackAll Trade.
MetaVia Inc. trades at $1.67 (+5.03%). Real-time quotes and charts are available on BlackAll Trade.
MetaVia Inc. has a market cap of about $0.01B.
MetaVia Inc., a clinical-stage biotechnology company, focuses on developing novel pharmaceuticals to treat cardiometabolic diseases. The company develops DA-1241, a novel G-Protein-Coupled Receptor 11